NEW YORK--(BUSINESS WIRE)--
Zamansky LLC announces that it is investigating AmerisourceBergen Corporation (ABC) (“AmerisourceBergen” or the “Company”) for potential breaches of fiduciary duties by its senior officers and board of directors. If you are a shareholder of AmerisourceBergen who still holds your shares, please contact our firm for information.
On October 1, 2018, the Company announced that it will pay $625 million to resolve civil fraud charges over its sales of refilled syringes to cancer patients, double-billing and providing kick-backs to doctors. The Company previously settled criminal charges, paying $260 million in fines. The Company’s former Chief Operating Officer stands to receive a portion of a whistleblower payment, according to public reports.
According to Jake Zamansky, investment fraud attorney, these settlements and whistleblower allegations raise concerns that the Company’s officers and directors breached their fiduciary duties owed to the Company and its shareholders. The law firm is investigating a potential shareholder derivative action.
What AmerisourceBergen Shareholders Can Do
If you are a current long-term shareholder of AmerisourceBergen who still holds your stock, please contact us to review or discuss your legal rights. You may, without obligation or cost to you, email firstname.lastname@example.org or call the law firm at (212) 742-1414.
About Zamansky LLC
Zamansky LLC is a leading investment fraud law firm with experience handling securities, hedge fund, ERISA and other shareholder class action and derivative litigation. We are investment fraud attorneys who represent both individual and institutional investors. Our practice is nationally recognized for our ability to aggressively prosecute cases and recover investment losses.
To learn more about Zamansky LLC, please visit our website, http://www.zamansky.com.